TIDMPOLX
RNS Number : 3358W
Polarean Imaging PLC
17 April 2023
Polarean Imaging Plc
("Polarean" or the "Company")
Appointment of Dan Brague as consultant
Strategic counsel to the commercial team, refining XENOVIEW(TM)
sales plan
Polarean Imaging plc (AIM: POLX), the medical imaging technology
company, announces the appointment of Mr. Daniel ("Dan") Brague,
currently a Non-Executive Director of Polarean, as a consultant to
the Company with immediate effect.
Dan Brague will provide strategic advice to the Polarean
commercial team to help refine its marketing and sales plans for
the Company's drug device combination product, XENOVIEW(TM) (xenon
Xe 129 hyperpolarised).
Dan is a highly accomplished executive leader with a background
focused on enterprise growth and value creation, who joined the
Board of Polarean as a Non-Executive Director in May 2022. He has
spent more than 25 years in the healthcare sector with over 20
years in diagnostic imaging, and a proven track record across sales
& marketing, product innovation, finance and business strategy.
His most recent executive role was as CEO of Curium North America,
a leading global manufacturer of radiopharmaceuticals, specifically
including inhaled gas radioisotopes.
Dan will retain his position on the Board as a Non-Executive
Director and Chairman of the Remuneration Committee.
Under the terms of the consultancy contract, Polarean will pay
Dan an hourly fee of US$300. This fee is capped at US$100,000 in
total.
The consultancy agreement with Dan amounts to a related party
transaction within the meaning of the AIM Rules for Companies (the
"AIM Rules"). The Directors who are independent of the related
party transaction (being all the Directors other than Mr. Dan
Brague) having consulted with Stifel, the Company's nominated
adviser, consider the terms of the consultancy agreement to be fair
and reasonable insofar as the shareholders of the Company are
concerned.
Richard Hullihen, CEO of Polarean Imaging plc said: "Dan brings
significant experience in the commercialisation of innovative
medical imaging products worldwide, including pulmonary
diagnostics. His specific background in the US healthcare
environment, reimbursement, and market development will be
invaluable as we look to execute our commercialisation strategy for
XENOVIEW(TM) ."
Commenting on his appointment, Dan Brague said: "Having served
on the Polarean Board since May 2022, I am a strong believer in the
potential of XENOVIEW(TM) to meet the clinical need for a
non-invasive diagnostic technology for the over 30 million
Americans that suffer from a chronic lung disease. I am pleased to
be able to use my experience to support the Polarean team in its
commercialisation activities."
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Kenneth West, Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare
Investment Banking)
Nick Adams / Nick Harland (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Anna Dunphy / Phillip Marriage Mob: +44 (0)7876 741 001 / +44 (0) 7867
984 082
About Polarean ( www.polarean.com )
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, medical imaging
technology companies operating in the high-resolution medical
imaging space. Polarean aspires to revolutionize pulmonary medicine
by bringing the power and safety of MRI to the respiratory
healthcare community in need of new solutions to evaluate lung
function, diagnose disease, characterize disease progression, and
monitor response to treatment. By researching, developing, and
commercializing novel imaging solutions with a non-invasive and
radiation-free functional imaging platform, Polarean's vision is to
help address the global unmet medical needs of more than 500
million patients worldwide suffering with chronic respiratory
disease. Polarean is a leader in the field of hyperpolarization
science and has successfully developed the first and only
hyperpolarized MRI contrast agent to be approved in the United
States. On December 23, 2022, the FDA granted approval for
Polarean's first drug device combination product, XENOVIEW(TM)
(xenon Xe 129 hyperpolarized). (129) Xe MRI is also currently being
studied for visualization and quantification of gas exchange
regionally in the smallest airways of the lungs, across the
alveolar tissue membrane, and into the pulmonary bloodstream for
future clinical indications.
About Xenoview
Indication
Xenoview, prepared from the xenon Xe 129 Gas Blend, is a
hyperpolarised contrast agent for use with magnetic imaging (MRI)
for evaluation of lung ventilation in adults and paediatric
patients aged 12 years and older.
Limitations of Use
Xenoview has not been evaluated for use with lung perfusion
imaging.
Important Safety Information
Contraindications
None.
WARNINGS AND PRECAUTIONS
Risk of Decreased Image Quality from Supplemental Oxygen :
Supplemental oxygen administered simultaneously with XENOVIEW
inhalation can cause degradation of image quality. For patients on
supplemental oxygen, withhold oxygen inhalation for two breaths
prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.
Risk of Transient Hypoxia : Inhalation of an anoxic gas such as
XENOVIEW may cause transient hypoxemia in susceptible patients.
Monitor all patients for oxygen saturation and symptoms of
hypoxemia and treat as clinically indicated.
ADVERSE REACTIONS
Adverse Reactions in Adult Patients : The adverse reactions
(> one patient) in efficacy trials were oropharyngeal pain,
headache, and dizziness.
Adverse Reactions in Pediatric Patients : In published
literature in paediatric patients aged 6 to 18 years, the following
transient adverse reactions were reported: blood oxygen
desaturation, heart rate elevation, numbness, tingling, dizziness,
and euphoria. In at least one published study of paediatric
patients aged 6 to 18 years, transient decrease in SpO2% and
transient increase in heart rate were reported following
hyperpolarised xenon Xe 129 administration. XENOVIEW is not
approved for use in paediatric patients less than 12 years of
age.
See full U.S. Prescribing Information at www.xenoview.net
XENOVIEW has received marketing approval in the United States
and not in other countries.
XENOVIEW(TM) is a trademark of Polarean, Inc.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEANLLFLPDEFA
(END) Dow Jones Newswires
April 17, 2023 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2024 to May 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From May 2023 to May 2024